Results 331 to 338 of about 264,642 (338)
Some of the next articles are maybe not open access.
Science Signaling, 2017
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire +2 more sources
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire +2 more sources
PD-L1 expression in meningiomas
Journal of Clinical Neuroscience, 2018The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies.
openaire +3 more sources
Immunotherapy, 2017
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol +3 more
openaire +4 more sources
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol +3 more
openaire +4 more sources
Cancer Research, 2016
Abstract Background: PD-1/PD-L1 directed antibodies are emerging as effective therapeutics in multiple oncology settings. Keynote 001 and Checkmate 057 have shown more frequent response to PD-1 targeted therapies in NSCLC patients with high tumour PD-L1 expression than patients with low or no PD-L1 expression.
Marianne Ratcliffe +5 more
openaire +2 more sources
Abstract Background: PD-1/PD-L1 directed antibodies are emerging as effective therapeutics in multiple oncology settings. Keynote 001 and Checkmate 057 have shown more frequent response to PD-1 targeted therapies in NSCLC patients with high tumour PD-L1 expression than patients with low or no PD-L1 expression.
Marianne Ratcliffe +5 more
openaire +2 more sources
Arkhiv patologii, 2019
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.Differences were found in the incidence ...
E. P Kulikov +8 more
openaire +3 more sources
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.Differences were found in the incidence ...
E. P Kulikov +8 more
openaire +3 more sources
RSC Medicinal Chemistry
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo +5 more
openaire +2 more sources
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo +5 more
openaire +2 more sources
Expression of PD-L1 in mastocytosis
Journal of the American Academy of Dermatology, 2016Lawrence F. Kuklinski, Jinah Kim
openaire +3 more sources